This chapter of CNS Drug Discoveries focuses on the Alzheimer' s disease and
Parkinson' s disease sectors of the market for neurodegenerative drugs.
Approximately US$6.6 billion was spent in 2005 on the symptomatic treatment of
Alzheimer' s disease (AD) and Parkinson' s disease (PD). Although these
neurodegenerative diseases only affect around 1% of the population their
prevalence increases with age, thus these diseases are likely to become more
commonplace due to patient demographics and become a greater burden on health
care services.
Global Alzheimer' s and Parkinson' s market In 2005, approximately 45% of AD/PD
sales were derived from the US compared to 36% in Europe and the remainder
(19%) in international markets including Japan. The sale of AD and PD
medication varies between each country, for example 55% of AD drug sales are
derived from the US compared to 31% of PD drug sales. The treatment of AD
patients is dominated by the use of acetylcholinesterase inhibitors such as
Aricept (Eisai), Exelon (Novartis) and Razadyne (Johnson & Johnson) although
the use of the NMDA receptor antagonist Namenda/Ebixa (Forest/Lundbeck) is
gaining acceptance, particularly in the treatment of moderate to severe AD. In
contrast, PD patients are treated with a cocktail of drugs but predominantly
with dopaminergic drugs such as Levodopa and/or dopamine agonists either as a
monotherapy or in combination with catechol O-methyltransferase (COMT)
inhibitors or monoamine oxidase (MAO) inhibitors.
Over the next six years, we forecast the market will undergo a new wave of
treatments as the first disease-modifying agents (those that address the
underlying cause of the diseases rather than the symptoms) are launched. These
include Alzhemed (Neurochem), Flurizan (Myriad Genetics) and phenserine
(Axonyx) for the treatment of AD and spheramine (Schering AG) for the
treatment of PD.
Table of Contents
NEURODEGENERATION
EXECUTIVE SUMMARY
THE FACTS
What is neurodegeneration and why are we interested in it?
PATIENT STATISTICS
Incidence, diagnosis rates and treatment; now and in the future
PATIENT MODEL
The addressable AD and PD patient population will grow by 2% per annum
Summary of AD patient population forecasts 2005A-2012E
Summary of PD patient population forecasts 2005A-2012E
DRUG GROWTH DRIVERS
DRUG GROWTH RISKS/DAMPENERS
GLOBAL AD/PD MARKET
Global CNS Market (US$68.7 billion)
GLOBAL SALES SPLIT
AD and PD Global sales split (2005A)
AD Global sales split (2005A)
PD Global sales split (2005A)
US market
AD US drugs sales split (2005A)
PD US drugs sales split (2005A)
European market
AD European drugs sales split (2005A)
PD European drugs sales split (2005A)
Japan
Split between AD and PD in Japan (2005A)
The major players
Market Share of AD players by sales (Dec 2005A)
Market Share of PD players by sales (Dec 2005A)
Players and Products in 2012
Market Share of AD players by sales (Dec 2012E)
Players and Products in 2012
Market Share of PD players by sales (Dec 2012E)
CURRENT AD TREATMENTS
CURRENT PD TREATMENTS
Leading Brands
Comparison of leading AD drugs
Comparison of leading PD drug classes
Patent Exposure of Current Products
Patent Exposure of Leading AD Brands
Patent Exposure of Leading PD Brands
ANALYSIS OF LEADING BRANDS
AD Agents
PD Agents
Acetylcholine Esterase (AChE) Inhibitors
Aricept (Eisai)
Exelon (Novartis)
Razadyne (Johnson & Johnson/Shire)
NMDA Antagonist
Namenda/Ebixa (Forest/Lundbeck)
Dopamine Agonists
Apokyn (Britannia/Vernalis)
Neupro (Schwarz Pharma)
Sifrol/Mirapex/Mirapexin (Boehringer Ingelheim)
Requip (GlaxoSmithKline)
Monoaminoxidase (MAO) Inhibitors
Azilect (Lundbeck/Teva)
Catechol-O-Methyltransferase (COMT) Inhibitors
Comtan/Comtess & Stalevo (Novartis)
GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2005 - 2012
Sales Forecasts of Current Leading AD Drugs
Sales Forecasts of Current Leading PD Drugs 2005 - 2012
Model assumptions
NEW DRUGS IN R&D
Drugs in Development to Treat AD and PD
ANALYSIS OF PHASE III DRUGS
New Drugs in Phase III Development to Treat AD and PD
AD Agents
PD Agents
AD Agents
Alzhemed (Neurochem)
Flurizan (Myriad Genetics)
Phenserine (Axonyx)
Xaliproden (sanofi-aventis)
Parkinson' s Disease
E2007 (Eisai)
Istradefylline (Kyowa Hakko)
Safinamide (Newron)
SLV308 (Solvay)
Spheramine (Schering AG/Titan)
GLOBAL SALES FORECASTS OF PHASE III AD and PD DRUGS 2006 - 2012
Sales Forecasts of Phase III Developmental AD and PD Drugs
Model assumptions
ANALYSIS OF PHASE II DRUGS
New Drugs in Early Clinical Development to Treat AD and PD
AD Agents
PD Agents
AD agents
Bapineuzumab (Wyeth/Elan)
Other promising Phase II drugs
CX717 (Cortex Pharmaceuticals)
EVT 101 (Evotec)
Ketasyn (Accera)
MEM 1003 (Memory Pharmaceuticals)
PBT2 (Prana)
SGS-742 (Saegis Pharmaceuticals)
PD drugs
SR 57667 (sanofi-aventis)
Talampanel (IVAX)
VR040 (Vectura)
COMPETITOR RATIO ANALYSIS PRODUCTS/DRUGS
CR Analysis of AD Agents Approved by 2012 - Based on Drug Class
CR Analysis of PD Agents Approved by 2012 - Based on Drug Class
COMPETITOR RATIO ANALYSIS - COMPANIES
CR Analysis of AD and PD Agents Approved by 2012 - Based on Company
WINNERS & LOSERS
Summary of Key Companies and Drugs in the AD and PD Market by 2012
DISCONTINUATION OF DRUGS
AD and PD drugs discontinued from clinical development
医薬品
その他のカテゴリ
FAQ